Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Vincristine 6Doxorubicin 5Cyclophosphamide 5merphos 4Specimen Handling 4Radiotherapy 4Prednisone 4Methotrexate 4pegaspargase 3calaspargase pegol 3Prednisolone 3Methylprednisolone 3Hydrocortisone 3Etoposide 3Daunorubicin 3Cytarabine 3Biopsy 3Asparaginase 3exifone 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Thioguanine 2Spinal Puncture 2Mercaptopurine 2Medrol Veriderm 2Magnetic Resonance Spectroscopy 2Filgrastim 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Injections × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡